ArticleImaging neuroscience (Cambridge, Mass.)2025
Dopamine alters functional gradients in Parkinson's disease.
Article in Imaging neuroscience (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Blunted modulation of hierarchical brain organization in opioid use disorder.Research square · 2026Article
- Cortical functional hierarchy disruption following subcortical stroke.BMC medicine · 2026Article
- Network hierarchy in Alzheimer's and Lewy body spectrum disorders: functional gradients, cognitive phenotypes, and translational gaps.Frontiers in aging neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromodulators regulate large-scale brain network topology to support adaptive behaviour. Disease models offer a unique window into how neuromodulatory systems impact large-scale brain network organisation. Here, we take advantage of Parkinson's disease-with its profound dopaminergic loss and pro-dopaminergic treatment strategies-to inform how dopamine may influence large-scale brain organisation. In 27 people with Parkinson's disease, resting-state scans were obtained on their regular dopamine medication and following overnight withdrawal of medication. Nineteen matched controls provided normative data. Gradients of brain organisation were examined using dimensionality reduction techniques. For single gradients, when individuals were on their dopamine medication, we observed a shift in higher-order networks towards somatomotor anchors. When interrogated in the multi-dimensional gradient space, we found that dopamine medication enhanced separation between functionally discrete sensory and higher-order networks. This increase in dispersion was dependent on an individual's dopamine dose level, and increased dispersion was more apparent in regions enriched with dopamine receptor (DRD2) gene expression. Together, these findings substantiate a role for dopamine in modulating large-scale functional brain organisation. Our findings further confirm that medication targeting the dopamine system may achieve its benefit by restoring aspects of network topology, and suggest new hypotheses about how dopamine medication is influencing large-scale functional brain organisation in Parkinson's disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.